Tesamorelin Off Label Use: What You Should Know

Tesamorelin is FDA-approved for exactly one purpose: reducing excess visceral abdominal fat in adults living with HIV-associated lipodystrophy. Tesamorelin off label use means a clinician prescribes that same drug for a different goal, dose, or patient group than the label describes — most often general fat loss or body-composition changes in people who are HIV-negative. Off-label prescribing is legal in the United States, but legal is not the same as proven safe or effective.

What Tesamorelin Is Actually Approved For

Sold as Egrifta and now as generic tesamorelin, the drug is a synthetic analog of growth hormone-releasing hormone (GHRH). It signals the pituitary to release the body's own growth hormone, which then prompts the liver to produce IGF-1.

The approved indication is narrow and specific:

• Who: adults with HIV and excess visceral abdominal fat (lipodystrophy)
• What: reduction of visceral adipose tissue
• Dose: 1.4 mg or 2 mg injected subcutaneously once daily
• Not approved for: general weight loss, cosmetic fat reduction, anti-aging, or athletic performance

Any use outside that label — including in people who do not have HIV — is off-label by definition.

Common Off-Label Uses People Ask About

Interest in off-label tesamorelin centers on where fat sits rather than on total body weight. Goals people commonly raise with a clinician include:

• Reducing deep visceral belly fat in non-HIV patients
• Preserving muscle and improving body composition during a weight-loss phase
• Anti-aging or "growth hormone optimization" protocols
• Stacking with other peptides marketed for fat loss or recovery

The evidence behind these goals is uneven. The strongest human data come from HIV lipodystrophy trials, while data in healthy, HIV-negative adults are far thinner.

Factor	FDA-approved use	Typical off-label use
Population	Adults with HIV-associated lipodystrophy	HIV-negative adults
Primary goal	Reduce visceral abdominal fat	Fat loss, body composition, anti-aging
Dose	1.4 mg or 2 mg daily	Often 1–2 mg daily, self-directed
Evidence quality	Randomized controlled trials	Limited, extrapolated, or anecdotal
Insurance coverage	Sometimes, with a matching diagnosis	Rarely covered

What the Research Does and Doesn't Show

In HIV lipodystrophy trials, tesamorelin cut visceral fat by roughly 15–20% over about six months, and the effect largely reversed after the drug was stopped. That is the core body of evidence.

Extrapolating to people without HIV assumes the same response in a different hormonal environment. That assumption is plausible but unproven, because baseline visceral fat, IGF-1 levels, and glucose handling differ between the two groups.

Tesamorelin is not a weight-loss drug. Trials did not show large, consistent drops in total body weight, and it is not a replacement for diet, exercise, or FDA-approved obesity medications.

Off-Label Dosing and Cycling

There is no standard off-label dose. Because the label dose was studied in a different population, any protocol outside it is an educated guess built on that data.

Some users follow a tesamorelin 5 on 2 off schedule, injecting five days per week and pausing for two, hoping to limit IGF-1 buildup or injection fatigue. No clinical trial has tested whether that schedule keeps the benefits or lowers the risks.

Because tesamorelin is injectable, handling matters as much as dosing. Standard bac water use involves a preserved, multi-dose diluent; people who mix their own vials often ask, "can i use reconstitution solution instead of bacteriostatic water?" — the short answer is that plain sterile water or saline is intended for single use, so a multi-dose vial needs a preservative to limit bacterial growth.

People researching injectables sometimes also look up how to use bpc 157, but BPC-157 and tesamorelin are not interchangeable and have never been studied together in a controlled human trial.

Comparing Tesamorelin With Other Fat-Loss Peptides

When people weigh aod 9604 vs tesamorelin, the key difference is mechanism: AOD-9604 is a fragment of human growth hormone that does not appear to raise IGF-1, while tesamorelin raises your own growth hormone and IGF-1. That single distinction drives most of the differences in side-effect profile, monitoring needs, and regulatory status.

Naming aside, both are injectable peptides sold heavily online, and neither is approved for general weight loss.

Legal Status, Cost, and Sourcing

Tesamorelin is a prescription drug in the United States. A licensed clinician may prescribe it off-label, but buying it without a prescription is not legal.

Cost is a real barrier. Brand Egrifta can exceed $2,000 per month without coverage, and insurers generally pay only for the approved diagnosis. Cheaper "research grade" vials sold online are not approved for human use, and independent testing has repeatedly found mislabeled, underdosed, or contaminated peptides in that market.

Safety, Side Effects, and Who Should Avoid It

Reported side effects include injection-site reactions, joint and muscle pain, swelling, and numbness or tingling in the hands from carpal tunnel-like symptoms. Tesamorelin raises IGF-1 and can affect blood sugar, so people with diabetes or glucose intolerance need monitoring.

Tesamorelin is not appropriate for people with active cancer, pituitary tumors, or disrupted pituitary anatomy, and it is not used during pregnancy. Anyone considering tesamorelin off label use should discuss risks, monitoring labs, cost, and alternatives with a healthcare professional first.

Off-label use does not mean unregulated use — it means the prescriber carries the judgment call, and the patient carries the unknowns.

RELATED PEPTIDE TOPICTesamorelin research

COMMON QUESTIONS

Frequently Asked Questions

Is tesamorelin FDA-approved for weight loss?

No. Tesamorelin is approved only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, for cosmetic fat reduction, or for use in people without HIV.

Is off-label tesamorelin legal in the United States?

Yes. A licensed clinician can legally prescribe an FDA-approved drug for a use that is not on the label, which is called off-label prescribing. Buying tesamorelin without a prescription, such as from research-peptide websites, is not legal for human use.

Does tesamorelin reduce belly fat in people without HIV?

That has not been established in large randomized trials. The strongest evidence comes from HIV lipodystrophy studies, and while some smaller studies suggest visceral fat reductions in other groups, the effect size and long-term safety in HIV-negative adults remain uncertain.